Patent ID: 11890274
Assignee: JMM LICENSING LLC
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 7:
8. The method of claim 6, wherein the neoplastic disease or disorder is a genetically-driven neoplasia associated with mTORC1 hyperactivation selected from the group consisting of familial adenomatous polyposis (FAP), colon cancer, vascular neoplasms and anomalies, PTEN Hamartoma Tumor Syndrome (PHTS), PIK3CA mutations, mTORC1 gain-of function mutations, hypereosinophilic syndrome, renal cell carcinoma, Peutz-Jeghers Syndrome, Erdheim-Chester Disease, Chronic Myelogenous Leukemia, tuberous sclerosis complex (TSC), lymphangioleiornyomatosis (LAM), and Neuroendocrine tumors (NETs).